FIELD: biotechnology.
SUBSTANCE: group of inventions relates to immunology. Disclosed is an antigen-binding domain which binds EGFRvIII and contains CDR1 LC, CDR2 LC, CDR3 LC, CDR1 HC, CDR2 HC and CDR3 HC according to SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 22, SEQ ID NO: 23 and SEQ ID NO: 24. Also disclosed is a chimeric antigen receptor containing said domain, coding nucleic acids, a vector, a cell, as well as the use of said inventions in the manufacture of a medicinal agent, methods of creating a cell and producing a cell population, method of providing immunity, a method of treating a disease associated with EGFRvIII expression.
EFFECT: inventions can be used in therapy of diseases associated with expression of EGFRvIII, using adaptive transfer of cells.
67 cl, 18 dwg, 2 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2015 |
|
RU2751362C2 |
| COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN EXPRESSION | 2017 |
|
RU2795467C2 |
| CHIMERIC ANTIGENIC (CAR) RECEPTOR AGAINST CD123 FOR USE IN TREATING MALIGNANT TUMORS | 2015 |
|
RU2724999C2 |
| TREATMENT OF MALIGNANT NEOPLASM USING HUMANIZED CHIMERIC ANTIGEN RECEPTOR AGAINST BCMA | 2015 |
|
RU2751660C2 |
| TREATING CANCER USING A CHIMERIC ANTIGENIC CLL-1 RECEPTOR | 2015 |
|
RU2741120C2 |
| CHIMERIC HUMAN MESOTHELIOGEN ANTIGEN RECEPTORS AND USE THEREOF | 2014 |
|
RU2714902C2 |
| CHIMERIC ANTIGEN RECEPTORS FOR CANCER TREATMENT | 2017 |
|
RU2826270C2 |
| TREATMENT OF MALIGNANT TUMOR USING ANTI-CD19 ANTIGEN CHIMERIC RECEPTOR | 2015 |
|
RU2815417C2 |
| TYPES OF COMBINATION THERAPY USING CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS | 2017 |
|
RU2809160C2 |
| CD20 THERAPY, CD22 THERAPY AND COMBINATION THERAPY WITH CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR (CAR) K CD19 | 2016 |
|
RU2752918C2 |
